Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
US6951865B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2000 |
| Grant date | Oct 4, 2005 |
| Priority date | — |
| Expiry date | Oct 23, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof. Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula —(CR1R2)m— (wherein R1 and R2 are the same as or different from each other and each represents a C1-6 alkyl group etc.), —NR3— (wherein R3 represetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula —(CR6R7)p— (wherein R6and R7 are the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with C1-6 alkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted C1-6 alkyl group etc.; and the partial structure means a single or double bond.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.